Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...

Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...
TipRanks on MSN

Mereo says phase 3 Orbit, Cosmic studies do not achieve primary endpoints

Mereo BioPharma (MREO) announced results from the Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta. Neither study ...
MPR

Setrusumab Misses Primary Endpoint in Osteogenesis Imperfecta Studies

Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.
Fierce Biotech

Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.
BioWorld

Mereo and Ultragenyx stagger as phase IIIs in brittle bones fail

Two phase III studies of setrusumab, Orbit and Cosmic, for treating brittle bones have failed and left the developers ...

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.
Pharmabiz

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...